Md. Code Ann., Ins. § 18-120
Prohibited acts relating to long-term insurance sales, marketing, and genetic tests
Effective Oct 1, 2008Added by Acts 1997, c. 35, § 2, eff. Oct. 1, 1997. Amended by Acts 2001, c. 731, § 1, eff. July 2, 2001; Acts 2008, c. 631, § 1, eff. Oct. 1, 2008; Acts 2008, c. 632, § 1, eff. Oct. 1, 2008.State of Maryland
(a)
- (1) In this section the following words have the meanings indicated.
(2)
(i) “Genetic information” means information derived from a genetic test:
- 1. about chromosomes, genes, gene products, or inherited characteristics that may derive from an individual or a family member;
- 2. not obtained for diagnostic and therapeutic purposes; and
- 3. obtained at a time when the individual to whom the information relates is asymptomatic for the disease, disorder, illness, or impairment to which the information relates.
(ii) “Genetic information” does not include information:
- 1. relating to a disease, disorder, illness, or impairment that is or has been manifested or for which the individual is or has been symptomatic; or
2. derived from:
- A. routine physical measurements;
- B. chemical, blood, and urine analyses;
- C. tests for the use of drugs;
- D. tests for the presence of the human immunodeficiency virus; or
- E. tests for the purpose of diagnosing a manifested disease, disorder, illness, or impairment.
- (3) “Genetic services” means health services that are provided to obtain, assess, or interpret genetic information or the results of genetic tests.
(4)
- (i) “Genetic test” means an analysis of human DNA, RNA, chromosomes, proteins, or metabolites that detects genotypes, mutations, or chromosomal changes.
(ii) “Genetic test” does not include:
- 1. routine physical measurements;
- 2. chemical, blood, and urine analyses;
- 3. tests for the use of drugs;
- 4. tests for the presence of the human immunodeficiency virus; or
- 5. tests that are directly related to a manifested disease, disorder, illness, or impairment that could reasonably be detected by a health care professional with appropriate training and expertise in the field of medicine involved.
(b) In addition to the other practices prohibited under this article, a carrier or insurance producer of a carrier that provides long-term care insurance may not:
- (1) employ a method of marketing that induces or tends to induce the purchase of long-term care insurance through undue pressure;
- (2) use a method of marketing that fails to disclose in a conspicuous manner that a purpose of the method of marketing is solicitation of insurance, and that contact will be made by an insurance producer or carrier;
- (3) knowingly make a misleading representation or an incomplete or fraudulent comparison of policies or carriers to induce a person to lapse, forfeit, surrender, terminate, retain, pledge, assign, borrow on, or convert a policy or take out a policy with another carrier;
(4) request or require a genetic test to:
- (i) deny or limit the amount, extent, or kind of long-term care insurance coverage available to an individual; or
- (ii) charge a different rate for the same long-term care insurance coverage; or
(5) use a genetic test, the results of a genetic test, genetic information, or a request for genetic services to:
- (i) deny or limit the amount, extent, or kind of long-term care insurance coverage available to an individual; or
- (ii) charge a different rate for the same long-term care insurance.
(c) Notwithstanding subsection (b)(5) of this section, if the use is based on sound actuarial principles, the results of a genetic test or genetic information may be used to:
- (1) deny or limit the amount, extent, or kind of long-term care insurance coverage made available to an individual; or
- (2) charge a different rate for the same long-term care insurance.
Added by Acts 1997, c. 35, § 2, eff. Oct. 1, 1997. Amended by Acts 2001, c. 731, § 1, eff. July 2, 2001; Acts 2008, c. 631, § 1, eff. Oct. 1, 2008; Acts 2008, c. 632, § 1, eff. Oct. 1, 2008.
Formerly Art. 48A, § 649.1.